在接受西妥昔单抗治疗的晚期结直肠癌患者中，KRAS突变应被视为一个独立的预后因素吗？ - Suppr | 超能文献

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?

作者信息

Garassino Marina Chiara, Farina Gabriella, Rossi Antonio, Martelli Olga, Torri Valter

出版信息

J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195.

DOI:10.1200/JCO.2008.16.8195

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?在接受西妥昔单抗治疗的晚期结直肠癌患者中，KRAS突变应被视为一个独立的预后因素吗？

J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195.

2

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.KRAS突变作为接受西妥昔单抗治疗的晚期结直肠癌患者的独立预后因素。

J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.

3

To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.对于晚期结直肠癌中存在KRAS G13D突变的患者，是否给予抗表皮生长因子受体（EGFR）单克隆抗体治疗。

Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9.

4

KRAS status predicts response to cetuximab for metastatic colorectal cancer.KRAS状态可预测转移性结直肠癌对西妥昔单抗的反应。

ONS Connect. 2008 Aug;23(8):25.

5

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.结直肠癌肿瘤中的KRAS突变特征与西妥昔单抗反应特征显著重叠。

J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186.

6

Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.患有结直肠癌且KRAS分子状态异质性的患者对基于西妥昔单抗的化疗有反应。

J Clin Oncol. 2010 Dec 20;28(36):e756-8. doi: 10.1200/JCO.2010.30.5011. Epub 2010 Sep 20.

7

Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?西妥昔单抗治疗结直肠癌的获益预测因素：我们是否“迷失在翻译中”？

J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22.

8

Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.结直肠癌：西妥昔单抗、KRAS、BRAF、PIK3CA突变及其他相关研究

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.

9

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].[表皮生长因子受体信号通路突变与转移性结直肠癌的治疗]

Gan To Kagaku Ryoho. 2010 May;37(5):791-4.

10

Beyond the KRAS test.超越KRAS检测。

Eur J Cancer. 2009 Sep;45 Suppl 1:398-9. doi: 10.1016/S0959-8049(09)70063-2.

引用本文的文献

1

and mutations in metastatic colorectal cancer: future perspectives for personalized therapy.转移性结直肠癌中的基因突变：个性化治疗的未来展望

Gastroenterol Rep (Oxf). 2020 Jun 15;8(3):192-205. doi: 10.1093/gastro/goaa022. eCollection 2020 Jun.

2

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.结直肠癌的生物学复杂性：早期检测和个性化医疗生物标志物的见解

Therap Adv Gastroenterol. 2016 Nov;9(6):861-886. doi: 10.1177/1756283X16659790. Epub 2016 Aug 7.

3

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.超越KRAS：抗EGFR单克隆抗体治疗转移性结直肠癌疗效的预测因素

World J Gastroenterol. 2014 Aug 7;20(29):9732-43. doi: 10.3748/wjg.v20.i29.9732.